Evolving Landscape of Targeted Therapies
By
Springer Healthcare IME
FEATURING
Lizza Hendriks
By
Springer Healthcare IME
FEATURING
Lizza Hendriks
Join Dr. Lizza Hendriks from Maastricht University Medical Center as she presents an in-depth overview of the evolving landscape of targeted therapies in oncology. This video covers evidence-based strategies for developing targeted drugs, the role of biomarker-agnostic therapies in non-small cell lung cancer, and the integration of data analysis in clinical practice for optimal patient outcomes.
Key Topics:
• Development of targeted drugs
• Biomarker-agnostic therapies
• Clinical data integration for better decision-making
Access a downloadable transcript of this webinar at https://targeted-therapies-lung-cancer.ime.springerhealthcare.com/#chapter2
This is episode #2 of 4, and is part is part of an ACCME- and EACCME-accredited, Independent Medical Education program entitled, Biomarker-Positive Disease: A Personalized Approach to Selecting Targeted Therapies in Lung Cancer and Beyond.
To learn more about the full program or to CLAIM YOUR CREDITS, visit https://targeted-therapies-lung-cancer.ime.springerhealthcare.com/
---
This activity is supported by independent educational grants from Roche and Illumina.
Key Topics:
• Development of targeted drugs
• Biomarker-agnostic therapies
• Clinical data integration for better decision-making
Access a downloadable transcript of this webinar at https://targeted-therapies-lung-cancer.ime.springerhealthcare.com/#chapter2
This is episode #2 of 4, and is part is part of an ACCME- and EACCME-accredited, Independent Medical Education program entitled, Biomarker-Positive Disease: A Personalized Approach to Selecting Targeted Therapies in Lung Cancer and Beyond.
To learn more about the full program or to CLAIM YOUR CREDITS, visit https://targeted-therapies-lung-cancer.ime.springerhealthcare.com/
---
This activity is supported by independent educational grants from Roche and Illumina.
Comments 0
Login to view comments.
Click here to Login
